Native valve endocarditis caused by dysgonic fermenter type 2 bacilli.

A chronic alcoholic who had casual contact with dogs developed subacute tricuspid endocarditis caused by the unusual gram-negative bacillus dysgonic fermenter type 2 (DF-2). Despite recurrent pulmonary emboli, the patient had an apparent successful response to 6 weeks of penicillin therapy. Two weeks after discharge, he experienced congestive heart failure necessitating tricuspid valvulectomy.

Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia.

Cefonicid (Smith Kline & French Laboratories; D-75073) is a new parenteral cephalosporin with a markedly long half-life, high serum levels, and good in vitro activity against Haemophilus influenzae. Patients with community-acquired pneumonia were randomized 2:1 to receive cefonicid, 1 g daily (21 cases) or cefamandole, 1 g every 6 h (12 cases). The two groups were similar, except that the cefonicid patients were older (mean 42 versus 31 years).